A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants
With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard
of Care
Research Question:
Does the drug Litifilimab reduce disease in people with lupus?
Basic Study Information
Purpose:
You may be eligible to take part in the study because you have an autoimmune disease
known as “lupus.” In autoimmune diseases, the immune system sees the body’s own tissues
as “foreign” and attacks itself, resulting in inflammation. Systemic lupus erythematosus,
otherwise known as SLE, can affect many different parts of the body but frequently
involves the joints, skin, kidneys, blood cells, and mucus membranes (the lining of
the mouth, nose, throat, stomach, and intestines), which can result in symptoms such
as swollen joints, rash, foamy urine, changes in red or white blood cells, and oral
ulcers, among others. Only people who have been diagnosed with SLE for at least 6
months can take part in the study. The purpose of the study is to investigate if
the investigational study drug litifilimab (BIIB059) can reduce disease activity and
inflammation in people with active SLE compared to a placebo.
Location: University of Rochester Medical Center
Study Reference #: STUDY00006992
Lead Researcher (Principal Investigator)
Lead Researcher:
Jennifer Anolik, MD, PhD
Study Contact Information
Study Coordinator: Maria Allen
Phone: (585) 275-1632
Email: maria_allen@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search